Ankylosing spondylitis
From the Journals
Criteria found largely interchangeable for classifying radiographic axSpA
Ankylosing spondylitis by modified New York criteria and radiographic axial spondyloarthritis by Assessment of SpondyloArthritis international...
Conference Coverage
PROMIS tools provide useful data for managing rheumatology patients
LAKE BUENA VISTA, FLA. – The NIH PROMIS tools provide helpful, trackable data that can improve the care of rheumatology patients.
News
Hadlima approved as fourth adalimumab biosimilar in U.S.
Hadlima gets seven of Humira’s indications.
Conference Coverage
After prior TNFi in axSpA, taking secukinumab or another TNFi appear equivalent
MADRID – After stopping a prior TNF inhibitor, there was no advantage to switching to the anti–IL-17 biologic secukinumab over a different TNFi...
Conference Coverage
Flurry of new anti–IL-17 monoclonal antibodies show efficacy in axSpA
MADRID – Trial data with three new anti–interleukin-17 receptor monoclonal antibodies in axial spondyloarthritis are positive.
Conference Coverage
Flu vaccine succeeds in TNF inhibitor users
MADRID – The number needed to vaccinate to prevent one case of influenza among patients taking adalimumab is much lower than it is for healthy...
Conference Coverage
Quality standards aim to improve worldwide spondyloarthritis care
MADRID – The Assessment of SpondyloArthritis international Society (ASAS) has developed nine new quality standards to improve the management of...
Conference Coverage
Despite advances, imaging of axSpA remains an adjunctive tool
MADRID – Supported by data, experts agree that diagnosis and assessment of axSpA is aided but not dependent on imaging.
Video
Retention rates comparable for biosimilars, original drug in spondyloarthritis
MADRID – One-year treatment data drawn from registries in five Scandinavian countries.
Video
Treat-to-target slowly emerging in axial spondyloarthritis
MADRID – While randomized trial data are awaited, observational evidence and expert opinion support the strategy in axial spondyloarthritis.
From the Journals
Chronic opioid use may be common in patients with ankylosing spondylitis
About a quarter of patients diagnosed with ankylosing spondylitis receive at least 90 days of opioids in a year, based on an analysis of U.S....